Skip to content

Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal TME

Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal Total Mesorectal Excision

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02406118
Enrollment
49
Registered
2015-04-02
Start date
2015-03-01
Completion date
2022-12-01
Last updated
2021-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

transanal TME quality, CRM

Brief summary

The purpose of this study is evaluation of the safety and the efficacy of transanal total mesorectal excision.

Detailed description

Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.

Interventions

Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.

Sponsors

National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. age: 20-80 years 2. biopsy-proven adenocarcinoma of the rectum 3. clinical staging (c or yc): T0-3, N0-2, M0 4. Rectal cancer located 3-12 cm from the anal verge 5. ECOG performance status: 2 or less 6. BMI: less than 30

Exclusion criteria

1. Synchronous colon cancer or other malignancy 2. Obstructing rectal cancer 3. Pregnant or breast-feeding 4. Receiving any other study agents 5. Fecal incontinence 6. History of prior colorectal cancer or inflammatory bowel disease 7. Tumor size: more than 7cm in long diameter 8. CRM: mesorectal fascia involvement or less than 1 mm on MRI

Design outcomes

Primary

MeasureTime frameDescription
TME quality & circumferential resection margin (CRM)the day of trananal TMEThe quality of the mesorectum was determined using pathology reports and scored using three grades: * Complete: intact mesorectum with only minor irregularities of a smooth mesorectal surface. No defect is deeper than 5 mm, and there is no coning toward the distal margin of the specimen. There is a smooth circumferential resection margin on slicing. * Nearly complete: moderate bulk to the mesorectum, but irregularity of the mesorectal surface. Moderate coning of the specimen is allowed. At no site is the muscularis propria visible, with the exception of the insertion of the levator muscles. * Incomplete: little bulk to mesorectum with defects down onto muscularis propria and/or very irregular circumferential resection margin.

Secondary

MeasureTime frame
30-day postoperative complications1 month after surgery
Number of harvested Lymph Nodesthe day of surgery

Other

MeasureTime frame
2-year local recurrence free survival2 years after surgery
5-year overall survival5 years after surgery

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026